In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
Zhui Chen, cofounder of the now $6 billion Shanghai-based biotech Abbisko, recalled running a trial on a drug licensed to the German pharma Merck KGaA. Abbisko’s trial finished in 11 months, so quickly that Merck executives asked if Abbisko could train …